Leishmania pifanoi amastigote antigen P-4: Epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis

Infection and Immunity

Volumn 66, Issue 7, 1998, Pages 3100-3105

  Haberer, Jessica E ^a   Da Cruz, Alda Maria ^b   Soong, Lynn ^a   Oliveira Neto, Manoel P ^c   Rivas, Luis ^d   Mcmahon Pratt, Diane ^a   Coutinho, Sergio G ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPITOPE; GAMMA INTERFERON; LEISHMANIA VACCINE; PROTEIN P 4; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; LEISHMANIA BRAZILIENSIS; LEISHMANIA PIFANOI; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PURIFICATION; SKIN LEISHMANIASIS; T LYMPHOCYTE;

EID: 0031842731     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.7.3100-3105.1998     Document Type: Article

References (40)

1. Antunes, C. M. F., W. Mayrink, P. A. Magalhaes, C. A. Costa, M. N. Melo, M. Dias, M. S. M. Michalick, P. Williams, A. O. Lima, J. B. F. Vieira, and A. P. M. Schettini. 1986. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int. J. Epidemol. 15:572-580.
2. Barral-Netto, M., S. G. Reed, M. Sadigursky, and G. Sonnenfeld. 1987. Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes. Clin. Exp. Immunol. 67:11-19.
3. Bates, P. A. 1993. Axenic culture of Leishmania amastigotes. Parasitol. Today 9:143-146.
4. Carvalho, E. M., D. Correia-Filho, O. Bacellar, R. P. Almeida, H. Lessa, and H. Rocha. 1995. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 53:273-277.
5. Castës, M., Z. Maros, A. Martinez, D. Trujillo, P. L. Castellanos, A. J. Rondon, and J. Convit. 1989. Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy. Parasite Immunol. 11:211-222.
6. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56:3272-3279.
7. Coutinho, S. G., M. P. Oliveira, A. M. Da-Cruz, P. M. De Luca, S. C. Mendonça, A. L. Bertho, L. Soong, and D. McMahon-Pratt. 1996. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigen: immunologic patterns associated with cure. Exp. Parasitol. 84:144-155.
8. Coutinho, S. G., A. M. Da-Cruz, A. L. Bertho, M. A. Santiago, and P. De-Luca. 1998. Immunologic patterns associated with cure in American cutaneous leishmaniasis. Braz. J. Med. Biol. Res. 31:139-142.
9. Croft, M, Carter, L., Swain, S. L., and R. W. Dutton. 1994. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715-1728.
10. Cupilillo, E., G. Grimaldi, H. Momen, and S. M. Beverley. 1995. Intergenic region typing (IRT): a rapid molecular approach to the characterization and evolution of Leishmania. Mol. Biochem. Parasitol. 73:145-155.
11. + T cells associated with cure of human cutaneous leishmaniasis. Infect. Immun. 62:2614-2618.
12. Doyle, P. S., J. C. Engel, P. F. Pimenta, P. P. de Silva, and D. M. Dwyer. 1991. Leishmania donovani: long-term culture of axenic amastigotes at 37°C. Exp. Parasitol. 73:326-334.
13. Eperon, S., and D. McMahon-Pratt. 1989. I. Extracellular cultivation and morphological characterization of amastigote-like forms of Leishmania panamensis and L. braziliensis. J. Protozool. 36:502-510.
14. Greenblatt, C. L. 1980. The present and future of vaccination for cutaneous leishmaniasis, p. 259-285. In A. Mezrahi, I. Hertman, M. A. Klingberg, and A. Kohn (ed.), New development with human and veterinary vaccines. Alan R. Liss, Inc., New York, N.Y.
15. Hammer, J., E. Bono, F. Gallazzi, C. Belunis, Z. Nagy, and F. Sinigaglia. 1994. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180:2353-2358.
16. Howard, J. G., S. Nicklin, C. Hale, and F. Y. Liew. 1982. Prophylactic immunization against experimental leishmaniasis. I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J. Immunol. 129:2206-2212.
17. Kemp, M. A. S. Hey, K. Bendtzen, A. Kharazmi, and T. G. Theander. 1994. Th1-like human T-cell clones recognizing Leishmania gp63 inhibit Leishmania major in human macrophages. Scand. J. Immunol. 40:629-635.
18. + T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect. Immun. 61:5205-5213.
19. Kreutzer, R. D., N. Souraty, and M. E. Semko. 1987. Biochemical identities and differences among Leishmania species and subspecies. Am. J. Trop. Med. Hyg. 36:22-32.
20. Liew, F. Y., S. Millot, Y. Li, R. Lelchuk, W. L. Chan, and H. Zitner. 1989. Macrophage activation by interferon-gamma from host protective T cells is inhibited by interleukin (IL-3 and IL-4) produced by disease-promoting T cells in leishmaniasis. Eur. J. Immunol. 19:1227-1232.
21. Mendonça, S. C., P. M. De Luca, W. Mayrink, T. G. Restom, F. Conceição-Silva, A. M. Da-Cruz, A. L. Bertho, C. A. Da Costa, O. Genaro, V. P. Toledo, and S. G. Coutinho. 1995. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am. J. Trop. Med. Hyg. 53:195-201.
22. Murray, P. J., T. W. Spithill, and E. Handman. 1989. Characterization of integral membrane proteins of Leishmania major by Triton X-114 fractionation and analysis of vaccination effects in mice. Infect. Immun. 57:2203-2209.
23. Nascimento, E., W. Mayrink, C. A. da Costa, M. S. Michalick, M. N. Melo, G. C. Barros, M. Dias, C. M. Atunes, M. S. Lima, D. C. Taboada, and T. Y. Liu. 1990. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect. Immun. 58:2198-2203.
24. Pan, A. A., S. M. Duboise, S. Eperon, L. Rivas, V. Hodgkinson, Y. Traub-Cseko, and D. McMahon-Pratt. 1993. Developmental life cycle of Leishmania: cultivation and characterization of cultured extracellular amastigotes. J. Eukaryot. Microbiol. 40:213-223.
25. Peters, E., and R. Killick-Kendrick. 1987. The leishmaniases in biology and medicine. Academic Press, London, United Kingdom.
26. Rachmim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
27. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177.
28. Russo, D. M., A. Jardim, E. M. Carvalho, P. R. Sleath, R. J. Armitage, R. W. Olafson, and S. G. Reed. 1993. Mapping human T cell epitopes in Leishmania gp63. J. Immunol. 150:932-939.
29. Russo, D. M., S. J. Turco, J. M. Burns, and S. G. Reed. 1992. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. J. Immunol. 148:202-207.
30. Santiago, M., P. M. De-Luca, A. L. Bertho, R. B. G. Azeredo-Coutinho, and S. G. Coutinho. 1997. Analysis of intracellular cytokines in peripheral blood mononuclear cells from patients with American tegumentary leishmaniasis (ATL) by flow cytometry. Mem. Inst. Oswaldo Cruz 92(Suppl. 1):215.
31. Sidney, J., M-F. del Gercio, S. Southwood, V. H. Engelhard, E. Appella, H.-G. Rammensee, K. Falk, O. Rotzschke, M. Takiguchi, R. T. Kubo, H. M. Grey, and A. Sette. 1995. Several HLA alleles share overlapping peptide specificities. J. Immunol. 154:247-259.
32. Sidney, J. R., T. Kubo, P. A. Wentworth, J. Alexander, R. W. Chesnut, H. M. Grey, and A. Sette. 1996. Broadly reactive HLA restricted T cell epitopes and their implications for vaccine design, p. 169-186. In H. Stefan and E. Kaufmann (ed.), Concepts in vaccine development. Walter de Gruyter Publishing, Berlin, Germany.
33. Sinigaglia, F., and J. Hammer. 1995. Motifs and supermotifs for MHC class II binding proteins. J. Exp. Med. 181:449-451.
34. Skeiky, Y. A., J. A. Guderian, D. R. Benson, O. Bacelar, E. M. Carvalho, M. Kubin, R. Badaro, G. Trinchieri, and S. G. Reed. 1995. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin-12. J. Exp. Med. 181:1527-1537.
35. + cytotoxic T cells and Leishmania-infected macrophages. J. Exp. Med. 174:499-505.
36. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
37. Soong, L., K. Goldsmith, and D. McMahon-Pratt. Unpublished results.
38. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J. Immunol. 143:4244-4249.
39. Titus, R. G., F. J. Gueiros-Filho, L. A. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92:10267-10271.
40. Xu, D., and F. Y. Liew. 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84:173-176.